Investment Pitches

Pitch Summary:
In Q2, Mounjaro sales rose sharply to $3.8 billion and Zepbound reached $2.3 billion in revenue. However, EPS came in below consensus due to lower pricing and temporary supply disruptions. The market reacted to news that certain payers were shifting GLP-1 drugs off preferred formularies (insurance companys’ lists of approved drugs), raising concerns about future prescription growth. While the underlying demand remains robust, competitive dynamics and manufacturing constraints led to investor caution. Volatility in the broader weight-loss drug space also contributed to relative weakness. Despite short-term pricing concerns, we believe Lilly is well positioned for multi-year growth. Its leadership in obesity and diabetes treatments, combined with a promising late-stage pipeline in Alzheimer’s, immunology, and oncology, offers significant upside.

BSD Analysis:
Eli Lilly is a generational growth story in the pharmaceutical sector, utterly dominant in the multi-hundred-billion-dollar GLP-1 megatrend. The company's financial health is breathtaking, with full-year 2025 revenue guidance raised to a staggering range of $63.0 billion to $63.5 billion, after posting 54% year-over-year revenue growth in Q3 2025. Its margins are structurally superior, with a TTM Gross Profit Margin of 83.0%—significantly outpacing peers. This dual focus on high margins and a massive $27 billion commitment to new manufacturing plants is necessary to meet the extraordinary demand and secure future revenue. The high valuation is justified by its projected growth, making it a hallmark of a dominant growth company.

Pitch Summary:
AerCap Holdings (AER) – AER delivered strong performance this quarter, bolstered by solid Q1 2025 results and a favorable UK court ruling on $1B in insurance claims related to the Russia-Ukraine War. With the largest aircraft portfolio in a seller’s market, AerCap is well-positioned to grow book value per share through strategic asset sales and stock buybacks, capitalizing on robust market dynamics.

BSD Analysis:
AerCap is the undisputed, high-quality global aircraft leasing titan whose stock is a conviction bet on the long-term, structural growth of air travel and its massive scale advantage. The core moat is its massive, diversified fleet (>1,700 aircraft, engines, and helicopters) and its ability to secure superior financing. The company's financial discipline is exceptional: Q3 2025 delivered record financial results and a 8.0% annualized net spread. The stock is a high-quality compounder, leveraging its scale to manage risk and consistently generate high margins from its long-duration, non-cancellable lease contracts.

Pitch Summary:
Armstrong World Industries, Inc. (AWI) – AWI shares outperformed in the quarter due to beating expectations, driven by increased volumes from recent acquisitions and an increase in pricing. We continue to like AWI for its consistent execution, strong financials, leading market share and persistent moats through its exclusivity agreements and warranties.

BSD Analysis:
Armstrong World Industries is a building products company with a strong competitive position in commercial ceiling systems and architectural solutions. Its products benefit from specification-driven demand, where architects and contractors prioritize performance, acoustics, and aesthetics over price. The business has increasingly shifted toward higher-margin systems and services, improving earnings quality. Construction cycles introduce volatility, but renovation and retrofit activity provide some counterbalance to new-build swings. Armstrong’s brand and distribution network make it difficult for smaller players to displace once specified. The balance sheet is solid, supporting disciplined capital allocation and bolt-on growth. This is a cyclical industrial with a surprising amount of pricing power when markets tighten.

Pitch Summary:
NewMarket Corporation (NEU) – NEU outperformed this quarter, fueled by strong AMPAC revenue growth from better volume and product mix, despite weaker Petroleum Additives results. The planned capacity expansion for the AMPAC business signals robust demand for rocket additives in a stable, oligopolistic market. Management prioritizes debt reduction and shareholder returns through dividends and buybacks.

BSD Analysis:
NewMarket operates in a high-margin corner of specialty chemicals, supplying additives that materially improve engine performance and longevity. Its products represent a tiny fraction of customer cost but a large portion of value delivered, supporting durable pricing power. Long-standing customer relationships and deep formulation expertise create meaningful barriers to entry. Demand is tied to global vehicle fleets and industrial equipment, making it steadier than new vehicle sales cycles. Capital intensity is low, and free cash flow conversion is consistently strong. While energy transition narratives create uncertainty, internal combustion fleets will persist for decades, sustaining the additive market. NewMarket is a textbook example of a boring business with exceptional economics.

Pitch Summary:
On the other side of the care continuum lies Encompass Health, one of the largest U.S. operators of inpatient rehabilitation hospitals. These facilities play a pivotal role in the recovery process for seniors after events like strokes, hip fractures, and cardiac surgeries — conditions whose frequency grows with age. Unlike acute-care hospitals or long-term skilled nursing facilities, Encompass focuses on intensive post-acute rehab — a cost-effective, outcomes-oriented model that’s increasingly favored by insurers and policymakers. Their facilities combine physical therapy, nursing, and medical care in a setting optimized for recovery and return-to-home metrics. Why we like it: • Exposure to rising procedure volumes with lower policy volatility • Real-estate-backed business model with stable occupancy and low turnover • Predictable cash flows and secular demand from an aging population. Despite volatility in other corners of healthcare, Encompass continues to deliver solid fundamentals — a reminder that longevity investing isn’t just about breakthrough science, but also about reliable care infrastructure.

BSD Analysis:
Encompass Health is the dominant pure-play operator in inpatient rehabilitation, a niche of healthcare that benefits directly from aging demographics and higher survival rates from acute events. Its facilities sit in a sweet spot of the care continuum, offering better outcomes at lower cost than long hospital stays or skilled nursing alternatives. The reimbursement framework is complex, but Encompass has the scale, clinical data, and operational discipline to manage it better than smaller peers. Labor is the biggest swing factor, yet staffing trends have begun to normalize, supporting margin recovery. Referral relationships with hospitals and physicians create a durable pipeline of patient volume that’s hard to disrupt. Capital allocation has been disciplined, focusing on de novo expansion and tuck-in acquisitions with attractive returns. This is a healthcare services business with real structural tailwinds, often mispriced as a simple reimbursement-risk story rather than a long-term compounding platform.

Pitch Summary:
Intuitive Surgical continues to be a prime beneficiary of the shift toward minimally invasive care — a preference that’s particularly pronounced among aging patients and hospitals managing resource constraints. The company’s Da Vinci robotic surgery systems are now deployed across thousands of hospitals globally, and Q2 2025 marked a record-setting quarter: 110 new placements, up from 70 the previous quarter. What drives this growth? In short: real-world demand. Hospitals increasingly prefer robotic-assisted procedures for their shorter recovery times, reduced infection risks, and greater surgical precision — all critical factors in aging populations undergoing hernia repair, prostatectomy, or cardiac surgery. Why we like it: • High-margin, recurring revenue from service contracts and surgical instruments • Strong balance sheet with no debt and a long runway for global adoption • A “pick-and-shovel” approach to rising surgical volumes in aging populations. As AI spreads into physical healthcare applications, Intuitive is well positioned at the intersection of automation, medicine, and demographic necessity.

BSD Analysis:
Intuitive Surgical is the undisputed, monopolistic king of robotic surgery whose stock is a conviction bet on the long-term, non-cyclical adoption of its da Vinci system. The core moat is its classic "razor-and-blade" business model: the massive installed base of da Vinci systems (the "razor") drives a massive, recurring, and high-margin revenue stream from proprietary instruments and accessories (the "blades"). The company continues to widen its technological gap with the launch of the da Vinci 5, which features 10,000x the computing power of its predecessor. This is an indispensable MedTech compounder, leveraging three decades of experience and 14 million procedures performed to secure its long-term dominance.

Pitch Summary:
Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed out the timing of a CRO growth recovery, even after multiple quarters of spending rationalization among its customers. We exited ICON due to the lowering of our confidence in the timing of CRO business normalization.

BSD Analysis:
ICON plc (ICON) ICON is the unavoidable CRO consolidator, capitalizing on the multi-year secular trend of pharmaceutical R&D outsourcing that major biopharma companies cannot reverse. The company’s massive scale, solidified by its acquisition of PRA Health Sciences, creates a structural competitive advantage that few rivals can match, making it a critical bottleneck supplier to the global drug development pipeline. While near-term growth has been pressured by cautious biotech funding, ICON is insulated by its sticky, high-dollar strategic partnerships with the largest pharmaceutical firms. The continued robust trailing twelve-month book-to-bill ratio over 1.2x proves that industry demand remains structurally intact, with any temporary stock weakness serving as an attractive entry point for a defensive, high-free-cash-flow compounder. ICON offers exposure to the massive biopharma R&D boom without the binary drug-development risk.

Pitch Summary:
We also initiated a position in U.K.-based Linde, a well-run company operating in an attractive, consolidated end market of industrial gas, which is a key input in many industries including technology, chemicals, manufacturing, health care and electronics. Both the company and the industry are highly disciplined in terms of price and contracting structure, providing downside protection in periods of slower economic growth. The stock’s relative multiple has recently declined due to macroeconomic pressure on sales volumes, providing an attractive entry point. We believe an overlooked feature of Linde’s business is its role as primary provider of gases for rocket propellant and coatings used by companies operating space and satellite businesses.

BSD Analysis:
Linde is a powerhouse oligopolist in the industrial gas sector, trading at a premium justified by its unbreakable moat and flawless execution of a capital-light, high-return model. The company's core competitive advantage is its unique vertical integration and its use of long-term, "take-or-pay" contracts with major customers. These contracts typically span 15 to 20 years and include cost pass-through clauses, effectively making Linde a utility that is immune to both economic downturns and commodity price volatility. This insulation ensures highly visible and stable cash flow, a characteristic almost unheard of in the industrial sector.Linde is aggressively pivoting toward the Clean Energy transition, leveraging its core expertise and infrastructure to dominate the nascent hydrogen supply chain. The company is building next-generation green hydrogen plants and has unparalleled experience in carbon capture and storage (CCUS), positioning it as the indispensable enabler of industrial decarbonization. With Gross Margins near 49% and Adjusted Operating Margins close to 30%, Linde continues to deliver best-in-class profitability driven by relentless productivity gains and synergy capture from its merger. The shares trade at a justified P/E premium given its structural stability and double-digit EPS growth potential, making it a defensive compounder with significant upside from the secular hydrogen boom.

Pitch Summary:
Our other focus was continuing to diversify the portfolio beyond traditional growth areas to gain exposure to attractive secular trends and prepare for wider large cap leadership. We did this through the purchase of two non-U.S. companies who are leaders in their industries. Netherlands-based Airbus, which designs and manufactures commercial aircraft, aerospace components and defense systems, stands to benefit from increasing long-term demand for commercial aircraft to support air travel. Aging of the existing fleet along with rising travel demand in relatively less penetrated regions like Asia–Pacific support a robust pipeline of replacement demand for Airbus for years to come. Airbus has a solid platform with the current A320 family before needing to scale up a new family of planes, putting the company in an attractive period for free cash flow growth. The company’s smaller defense segment also stands to benefit from the EU ramping up defense spending as the U.S. pulls back on its overseas security commitments.

BSD Analysis:
Airbus is the unavoidable duopoly giant in commercial aerospace, benefiting from a multi-year, record-high backlog that provides unassailable revenue visibility for the next decade. The investment thesis is a pure, leveraged play on the global need for more fuel-efficient aircraft, driven by airline fleet renewals and structural air traffic growth in emerging markets. The key catalyst is the successful and profitable ramp-up of A320neo family production rates to 75 aircraft per month by 2027, which will drive significant operating leverage and free cash flow generation over the next several years. The main risk—persistent supply chain constraints—is paradoxically a bullish indicator, as it solidifies the backlog and ensures that delivered aircraft command premium pricing in a capacity-constrained market. Airbus's strategic acquisition of former Spirit AeroSystems work packages is a necessary move to secure its own supply chain and enhance operational control, guaranteeing a consistent path to higher margins as production normalizes.

Pitch Summary:
The Strategy’s select growth exposure increased during the quarter due to the strong performance of the higher-beta stocks in this growth bucket as well as the purchase of ServiceNow. The company provides an end-to-end software-as-a-service (SaaS) platform to help enterprise customers automate and standardize business processes in areas like IT, customer services, sales and data security. ServiceNow also has a monetizable generative AI product being adopted by its customers. We have liked the business for a long time and took advantage of the April selloff to establish a position.

BSD Analysis:
ServiceNow is the indispensable backbone of enterprise workflow automation, commanding a premium valuation because it's the only platform fully capitalizing on the AI-driven shift in corporate efficiency.
The core investment thesis is built on an unbreakable ecosystem moat derived from extremely high switching costs and a near-perfect $120%+ Net Revenue Retention (NRR) rate. This means every customer not only stays but consistently spends more, funding the company's compounding growth. The true engine of the firm's future is its Generative AI suite, Now Assist, which is being integrated across every product line (ITSM, HR, Customer Service) to offer autonomous, human-level task completion. This AI layer is not a feature, it's a massive labor arbitrage tool that drives immediate, measurable Return on Intelligence (ROI) for clients by automating routine work. This has positioned ServiceNow to achieve a robust "Rule of 40" score (combining growth and profitability) and maintain 81% gross margins. While the 50x-60x forward P/E multiple appears lofty, it is justified by the company's superior profitability, $24 billion total backlog (RPO), and strategic partnerships with giants like NVIDIA and Microsoft that guarantee its role as an AI infrastructure leader for the next decade.

Pitch Summary:
We also added a starter position in Marvell Technology in June. Marvell is a company we have been tracking through our ownership of Nvidia and work on the AI semiconductor complex over the last several years. Similar to Broadcom, Marvell designs chips and networking equipment that power technologies like AI, cloud computing and 5G infrastructure and has a particularly strong interconnect business. While Marvell has a high-quality asset portfolio to compete in the custom application-specific integrated circuits (ASICs) chip business, the stock has lagged AI accelerator peers like Nvidia and Broadcom as its ramp in AI revenue has been slower than others in the ecosystem. We believe this dynamic can reverse in coming years as more of Marvell’s customer wins ramp up. Marvell’s valuation has compressed significantly over the past six to nine months and the stock now trades at a healthy growth-adjusted discount to AI semi peers, providing an attractive entry point.

BSD Analysis:
Marvell is a high-growth infrastructure semiconductor company executing a ruthless, successful pivot to become the custom silicon and high-speed interconnects supplier for the AI data center buildout. The entire investment thesis is anchored in the company's ability to be the "alternative" to NVIDIA, designing high-performance, cost-effective Application-Specific Integrated Circuits (ASICs) for hyperscalers like Amazon and Microsoft that need to lower their Total Cost of Ownership (TCO). This strategic shift is paying off with accelerating top-line growth: Data Center revenue is surging, recently growing 37% year-over-year. Marvell's core competitive moat is its "Compute + Connect" strategy, integrating custom chips with high-speed optical interconnects and networking switches. This complete stack is critical for running AI workloads efficiently and is driving Non-GAAP Gross Margins toward 60%. The company has deliberately divested low-margin businesses and authorized a $5 billion share repurchase program to shrink the share count, amplifying returns from its improving Free Cash Flow. This aggressive focus on the highest-value parts of the AI infrastructure supply chain positions Marvell as a compelling, high-growth semiconductor compounder.

Pitch Summary:
In the semiconductor sector, we trimmed our position in Taiwan Semiconductor to manage the risk amid intensified geopolitical tensions between the U.S. and China in 2025, directing the proceeds into the purchase of a position in Broadcom. Adding Broadcom, a leader in semiconductor design for communications and networking devices, enables the Strategy to better participate in the development of custom silicon chips for AI computing. Broadcom is well-positioned for continued healthy investment in AI, working with several large technology companies to develop custom silicon that we expect to grow alongside robust demand for Nvidia’s all-purpose GPUs. The company’s cloud infrastructure software business should also continue to grow for the next several years given its entrenched position within enterprises.

BSD Analysis:
Taiwan Semiconductor Manufacturing Company Limited is the unassailable design kingmaker of the semiconductor industry, holding a near-duopoly over the mission-critical Electronic Design Automation (EDA) market. The company's true growth engine is the Synopsys.ai suite, an AI-driven toolchain that automates complex chip design, drastically accelerating time-to-market and compounding productivity for every major chipmaker. The strategic logic is undeniable: the colossal $2 billion investment from NVIDIA permanently locks its tools into the dominant CUDA/GPU ecosystem for a strategic advantage. This non-cyclical software generates high-quality, time-based subscription revenue with best-in-class gross margins near 80%. The Ansys acquisition further solidified its verification moat, making the integrated platform structurally indispensable to the AI buildout. The stock's recent pullback was a massive market misjudgment, creating a clear entry point for a company poised to drive exponential ARPU expansion through its core design licenses.

Pitch Summary:
After making progress on margin expansion through the first half of 2024, mass market retailer Target has recently faced challenges from continued shifts in consumer spending away from discretionary categories, like home and electronics, which make up the majority of the company’s sales and carry higher margins. Tariffs on imports from China are likely to further pressure Target’s business. Despite the company’s efforts to protect margins in a difficult operating environment, we see risks weighted to the downside, leading us to exit the position.

BSD Analysis:
Target is still one of the strongest omni-channel retailers in the U.S., but the last two years reminded everyone that even great operators can get tripped by inventory swings and shifting consumer behavior. The good news: traffic has stabilized, inventory is far cleaner, and the company is regaining margin discipline after a painful reset. Target’s merchandising strength — especially in apparel, beauty, and home — continues to differentiate it from Walmart and Amazon, who can’t replicate its mix of curation and brand equity. The digital ecosystem remains a quiet powerhouse, with same-day services like Drive Up driving loyalty and high-frequency repeat behavior. While discretionary spend is soft, Target’s core shopper is still relatively healthy, and the company is leaning into owned brands that carry meaningfully higher margins. Long term, the combination of supply-chain modernization and better inventory control should restore earnings power. Markets still treat Target like a wounded retailer, but structurally it remains a well-run, omni-channel engine with plenty of recovery upside.

Pitch Summary:
Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed out the timing of a CRO growth recovery, even after multiple quarters of spending rationalization among its customers. We exited ICON due to our declining confidence in the timing of CRO business normalization.

BSD Analysis:
ICON is a high-quality Contract Research Organization (CRO) that has achieved unprecedented scale and efficiency, making it the definitive platform for outsourced drug development. The entire investment thesis is underpinned by the $12 billion acquisition of PRA Health Sciences, which eliminated a key competitor and created a dominant, top-tier CRO with over $8 billion in trailing revenue. This unmatched scale allows ICON to capture a growing share of the massive and complex clinical trial market, maintaining strategic partnerships with the world's largest biopharma companies. Despite near-term revenue pressures from trial delays, the core of its business is protected by a record $24.7 billion backlog and highly visible cash flow. Management is aggressively deploying its cash to amplify per-share growth, completing $750 million in buybacks year-to-date and achieving a substantial 21.2% Adjusted EBITDA margin. The future is secured by its investment in AI-enabled trial solutions (iSubmit, FORWARD+) and decentralized trials, which structurally accelerate drug development and boost profitability.

Pitch Summary:
In IT, we added Synopsys and Palantir Technologies. Synopsys is a leader in electronic design automation (EDA) software and custom chip designs, operating in a duopoly market with multiple avenues of growth driven by the increased complexity of semiconductor chips. The company’s EDA software and tools are mission critical and difficult to replicate, providing defense to its high-margin business model. Palantir is a software-as-a-service provider with an AI-powered operating system that connects data to existing customer applications. Palantir’s platform acts as a hub to improve business outcomes across government and commercial end markets, allowing users to synthesize diverse data sources into actionable insights in real time. The company is highly profitable and growing rapidly at scale with 80%+ gross margins. Given the stock’s more elevated valuation we are being mindful of position size.

BSD Analysis:
Palantir is the most controversial stock in tech, trading at an absurd valuation, but justified by its brutal transition from a government contractor to the definitive enterprise AI infrastructure. The core thesis is validated by the Artificial Intelligence Platform (AIP), which is driving exponential commercial acceleration, with U.S. Commercial revenue surging 121% year-over-year. Its true competitive moat is the "data-to-action" loop, enabling clients to securely deploy generative AI models that automate high-stakes operational decisions across their unique data Ontology, a capability few competitors can match. The seemingly insane 40x forward sales multiple is demanded by the market because of the 80% gross margins and the vast, sticky Annual Recurring Revenue (ARR) inherited from its high-security government legacy. Critics obsess over dilutive stock-based compensation (SBC), but the core business is now GAAP profitable, consistently generating $1.9-$2.1 billion in Adjusted Free Cash Flow. The stock is a high-conviction bet on the future of Western technological sovereignty, with every major defense and enterprise decision being built on its platform.

Pitch Summary:
In IT, we added Synopsys and Palantir Technologies. Synopsys is a leader in electronic design automation (EDA) software and custom chip designs, operating in a duopoly market with multiple avenues of growth driven by the increased complexity of semiconductor chips. The company’s EDA software and tools are mission critical and difficult to replicate, providing defense to its high-margin business model. Palantir is a software-as-a-service provider with an AI-powered operating system that connects data to existing customer applications. Palantir’s platform acts as a hub to improve business outcomes across government and commercial end markets, allowing users to synthesize diverse data sources into actionable insights in real time. The company is highly profitable and growing rapidly at scale with 80%+ gross margins. Given the stock’s more elevated valuation we are being mindful of position size.

BSD Analysis:
Synopsys is the unassailable design kingmaker of the semiconductor industry, holding a near-duopoly over the mission-critical Electronic Design Automation (EDA) market. The company's true growth engine is the Synopsys.ai suite, an AI-driven toolchain that automates complex chip design, drastically accelerating time-to-market and compounding productivity for every major chipmaker.
The strategic logic is undeniable: the colossal $2 billion investment from NVIDIA permanently locks its tools into the dominant CUDA/GPU ecosystem for a strategic advantage. This non-cyclical software generates high-quality, time-based subscription revenue with best-in-class gross margins near 80%. The Ansys acquisition further solidified its verification moat, making the integrated platform structurally indispensable to the AI buildout. The stock's recent pullback was a massive market misjudgment, creating a clear entry point for a company poised to drive exponential ARPU expansion through its core design licenses.

Pitch Summary:
In health care, we replaced Eli Lilly, a leading developer of GLP-1 treatments for diabetes and obesity, with its primary competitor Novo Nordisk. Novo’s Wegovy drug was first to market among the new generation of obesity drugs; however, the company has lost market share to Lilly due to delays in scaling up production. While the initial market reaction to Novo’s enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Eli Lilly. With Novo poised to have a better product portfolio and improved supply position, we find the company’s valuation very attractive given the large secular growth trends behind the diabesity market. We also added Alnylam Pharmaceuticals, a commercial stage biotechnology company and world leader in RNA interference, a technology that selectively shuts off the production of any protein at the genetic level. The company’s platform of five approved drugs can be used to treat a broad array of rare and common diseases as well as consistently generate new drug candidates. We do not believe the market appreciates the potential value of Alnylam’s core Amvuttra franchise to treat a liver condition that can lead to heart failure. It also has several early-stage pipeline assets, including opportunities in high blood pressure and Huntington’s Disease.

BSD Analysis:
Eli Lilly is a generational growth story in the pharmaceutical sector, utterly dominant in the multi-hundred-billion-dollar GLP-1 weight loss and diabetes space. The company's lead assets, Mounjaro (diabetes) and Zepbound (obesity), anchor the bull case, with its dual GLP-1/GIP mechanism providing a clinical edge over competitors. This unprecedented demand is driving a massive capacity buildout, with Lilly investing billions in new US and European manufacturing sites, a strategic move to ensure supply and effectively "outbuild" the competition. The company maintains superior, software-like gross margins exceeding 83%, and its non-GAAP operating margin is now guided to be over 45%, translating to immense profitability. The valuation, while commanding a premium P/E multiple (over 50x) that prices in aggressive growth, is justified by the pipeline optionality, including the potential blockbuster launch of Donanemab for Alzheimer's and the highly anticipated oral GLP-1, Orforglipron. Analysts project that Lilly's tirzepatide sales will surpass Novo Nordisk's by 2026, underscoring its pivotal role in the future of cardiometabolic medicine.

Pitch Summary:
Moody’s operates through two segments: Moody’s Investor Services (MIS), which generates about 70% of EBITDA, and Moody’s Analytics (MA), which contributes the remaining 30%. MIS benefits from an entrenched duopoly with S&P, enjoying >80% combined market share and high regulatory barriers that protect its moat. Revenue is cyclical with issuance but demonstrates durable growth over multi-year horizons, averaging 6%+ CAGR. Moody’s Analytics provides stability through >95% recurring subscription revenue and has expanded via acquisitions such as Bureau van Dijk, RDC, and RMS. The upcoming “refi wall” of $4.9T in corporate maturities, combined with rising high-yield issuance, should drive a tailwind for MIS. Pricing power remains strong as Moody’s fees are a fraction of the interest savings delivered to issuers. Emerging opportunities include rating and data services for the fast-growing private credit market. Technological investments, particularly in AI, are expected to enhance efficiency and margins. Despite cyclicality, Moody’s consistent free cash flow generation supports buybacks and positions it as a high-quality compounder with a clear runway for mid-teens EPS growth.

BSD Analysis:
Moody’s is a textbook example of a durable compounder with strong barriers to entry and a rational competitive landscape. The refinancing wave through 2028, combined with secular growth in private credit, offers multi-year catalysts for revenue growth. The Analytics segment, though smaller, provides an important diversification and could see margin expansion from SaaS scaling. Investors often underappreciate how issuance cyclicality resolves into longer-term recurring-like revenues, and the market may be underestimating the operating leverage and efficiency gains from AI integration. Risks remain in regulatory oversight and cyclical issuance volumes, but the duopoly structure and high switching costs offer a strong margin of safety. For long-term investors, Moody’s provides exposure to structural credit market growth with defensive cash flow and capital return potential.

Pitch Summary:
Charter is one of the largest US broadband providers with ~30M residential customers, whose stock direction is driven by broadband net adds and revenues. The pitch argues for 80% upside using 10x N24M FCF per share of $50, a level management has effectively guided toward by 2028. The long thesis rests on three legs: 1) Charter’s differentiated value proposition, offering lower broadband ARPUs, bundled streaming, and a fast-growing mobile business that improves churn; 2) competitors rationalizing, with fiber and fixed wireless raising ARPUs and focusing on returns rather than share grabs; and 3) industry broadband growth being at trough levels, with upside from household formation and penetration expansion. If Charter stabilizes net adds near breakeven, the market should assign 10x FCF rather than a “terminal zero” multiple. Current negative net adds of ~200k could improve with churn benefits and industry tailwinds, reversing sentiment. Risks include persistent share loss to fiber and wireless, but the asymmetry is favorable. The pitch views the market as overly pessimistic and underappreciating management’s strategy.

BSD Analysis:
BSD case: CHTR is priced as if in terminal decline, but structural advantages, rational competition, and trough industry growth set up for net add stabilization. At 10x FCF, shares re-rate significantly, making risk/reward attractive.

Pitch Summary:
Paywalled (The Bear Cave believes the stock of Pheton Holdings (NASDAQ: PTHL — $441 million) is being manipulated by overseas stock manipulation groups and is at risk of a near-term, severe stock collapse.)

BSD Analysis:
The Bear Cave critiques Pheton as a speculative small-cap with minimal disclosure, questionable governance, and tenuous ties to the healthcare IT narrative. Financial reporting is opaque, revenues are immaterial, and corporate structure raises concerns of related-party transfers. The short thesis emphasizes that Pheton is more promotion than business, surviving on retail speculation rather than commercial traction. Investors face asymmetric downside given the absence of sustainable operations.